CDC-RFA-JG-26-0058_DGHP FY26 ME Indicator List.pdf

DGHP Monitoring and Evaluation – Partner Level Indicators, February 2026

Division of Global Health Protection (DGHP) Monitoring and Evaluation

– FY 2026 JG-26-0058

Partner-level Indicators Overview Below is a menu of DGHP M&E Partner-Level Indicators that span five technical areas:

(1) Lab System Strengthening

(2) Quality Management Systems

(3) Laboratory Workforce

(4) Biorisk Management Systems

(5) Emergency Laboratory Preparedness and Response to Outbreaks

A comprehensive indicator menu inclusive of detailed descriptions of each indicator will be provided at time of award. DGHP partner-level indicators should be incorporated into the recipient’s Evaluation & Performance Measurement Plan (EPMP). The indicators shown below may change before award or in future years.

Partner-level Indicators

1. Lab System Strengthening Indicators

1.1. Strengthening public health laboratory systems and

services at multiple levels of the network

1.1.1. Number of training tools developed for testing, biosafety, laboratory quality, and biosecurity.

1.1.2. Number of training of trainer (TOT) sessions held by training for testing, biosafety, laboratory quality, biosecurity.

1.1.3. Number of supported sites that received non-training related technical assistance.

1.1.4. Number of laboratories supported with the development of national standards.

1.1.5. Number and proportion of countries that have developed or strengthened a national laboratory specimen referral system and transport network.

1.1.6. Number of laboratories with established diagnostic and pathogen characterization strategies and frameworks at each tier of the laboratory network for priority diseases

1.1.7. Number of laboratories with improved use of modern, safe, secure, affordable, and appropriate point-of-care diagnostic tests and core sequencing activities within the laboratory network

1.1.8. Number of new diagnostic tests established in national or regional laboratories.

2. Quality Management Systems Indicators

2.1. Improve laboratory quality management systems to

respond to future outbreaks and health emergencies

2.1.1. Number and proportion of countries that have adopted and implemented a national program of quality management systems

2.1.2. Number of rounds of proficiency testing performed for supported sites conducting testing in any of three areas: molecular, antibody, and/or antigen.

2.1.3. Number of supported sites participating in External Quality Assurance Programs (EQAP)

2.1.4. Number of supported sites with laboratory staff participating in approved Proficiency Testing (PT) programs

2.1.5. Number of supported sites requesting quality assurance and/or quality control technical assistance

2.1.6. Number of supported sites participating in EQAP that achieved successful/passing score.

2.1.7. Number of supported sites participating in EQAP that achieved a score of 100%.

2.1.8. Number of supported sites that participated in EQAP and did not achieve a successful result for every sample in the panel (qualitative) or scored less than 100% (quantitative)

2.1.9. Number of supported sites participating in EQAP and/or approved PT programs and did not achieve a successful result that documented what corrective action would be, or was, taken to address unsuccessful results.

2.1.10. Number of supported sites participating in EQAP that achieved less than 100% score in more than one consecutive round.

2.1.11. Number of supported sites participating in approved PT programs that achieved a score of 100%.

2.1.12. Number of supported sites that participated in approved PT and did not achieve a successful result for every sample in the PT panel (qualitative) or scored less than 100% (quantitative) that documented what corrective action would be, or was, taken to address unsuccessful results.

2.1.13. Have you supported laboratories in the supported country to implement routine specimen referral systems and transport networks with defined and tracked turnaround time targets?

2.1.14. Number of data or digital systems developed or maintained.

2.1.15. Number of laboratory staff participating in approved PT programs that achieved successful/passing score.

2.1.16. Number of laboratory staff that participated in approved PT programs and did not achieve a successful/passing score.

3. Laboratory Workforce Indicators

3.1. Develop a robust, skilled, and resilient public health

laboratory workforce to respond to future outbreaks and health emergencies

3.1.1. Number of risk mitigation strategies that have been implemented that are tailored to the needs of specific populations

3.1.2. Proportion of frontline workers that had an increase in awareness and knowledge to plan and implement Risk Communications and Community Engagement (RCCE) interventions at various levels as determined by pre- and post- test assessment

3.2. Community Mitigation

3.2.1. Number of GLLP participants in each implementation by sector.

3.2.2. Number of GLLP mentors in each implementation by sector.

3.2.3. Mean score improvement between pre and post-tests for each GLLP module.

3.2.4. Status of GLLP implementation.

3.2.5. Number of TOT participants who trained staff on testing, biosafety, laboratory quality, biosecurity.

3.2.6. Number of participants trained by training area for testing, biosafety, laboratory quality, biosecurity.

3.2.7. Number of staff documented as receiving laboratory training with certificate of completion for testing, biosafety, laboratory quality, biosecurity.

3.2.8. Number of staff certified as competent in testing, biosafety, laboratory quality, biosecurity.

3.2.9. Number of human and animal health laboratory staff trained in the latest diagnostic methods (e.g., serology, molecular, whole genome sequencing)

4. Biorisk Management Systems Indicators

4.1. Identify and mitigate biological risks to ensure the

safety and integrity of our public health laboratory operations

4.1.1. Number and proportion of designated laboratories that have biorisk management policies and regulatory framework and physical security controls for potential high consequence pathogens and toxins.

4.1.2. Number of laboratories compliant with international standards for biosafety and biosecurity in line with WHO biorisk management strategy.

4.1.3. Number of laboratories with established biosafety cabinet preventative maintenance plans.

4.1.4. Number of laboratories with completed biorisk assessments.

4.1.5. Number of laboratories with established biosafety and biosecurity training programs.

4.1.6. Number of laboratories with established and implemented specimen management, disposal and inventories for potential high consequence pathogens and toxins.

5. Emergency Laboratory Preparedness and Response to Outbreaks Indicators

5.1. Reinforce emergency laboratory preparedness and

response to quickly detect, identify, and report outbreak pathogens

5.1.1. Number of last-mile (in-country) deliveries of laboratory goods for

[insert order type] financially supported and completed.

5.1.2. Number of last-mile (in-country) deliveries of laboratory goods for [insert order type] financially supported and completed under appropriate storage and transport conditions.

5.1.3. Number of consignees that received financial and/or logistics support for procurement of laboratory reagents and/or other supplies necessary to conduct laboratory testing.

5.1.4. Number of laboratories (within a national laboratory system) with established real-time bio-surveillance of pathogens of pandemic potential.

Performance reports will be based on which Notice of Funding Opportunity (NOFO) activities and outcomes are identified in the logic model. Performance reports will be submitted to CDC in accordance with the requirements listed under this NOFO and overall performance will be reviewed on regular technical calls as well as through joint strategic review meetings.